


Palbociclib hydrochloride

Cat. No.:	HY-50767C
CAS No.:	571189-11-2
Molecular Formula:	C ₂₄ H ₃₀ ClN ₇ O ₂
Molecular Weight:	514.99
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	4°C, sealed storage, away from moisture
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H₂O : 2 mg/mL (3.88 mM; ultrasonic and warming and heat to 60°C)
DMSO : 1.25 mg/mL (2.43 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.9418 mL	9.7089 mL	19.4179 mL
	5 mM		---	---	---
	10 mM		---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma^{[1][3][4]}.

IC₅₀ & Target

DYRK1A 2000 nM (IC ₅₀)	MAPK 8000 nM (IC ₅₀)	Cdk4/cyclin D3 9 nM (IC ₅₀)	Cdk4/cyclin D1 11 nM (IC ₅₀)
Cdk6/cyclin D2 16 nM (IC ₅₀)			

In Vitro

Palbociclib (0-1 μM, 24 h) hydrochloride inhibits retinoblastoma phosphorylation at Ser⁷⁹⁵ in MDA-MB-435 cells with an IC₅₀ value of 0.063 μM, and obtains similar effects on both Ser⁷⁸⁰ and Ser⁷⁹⁵ phosphorylation in the Colo-205 colon carcinoma^[1]. Palbociclib (0-10 μM, 24 h) hydrochloride arrests MDA-MB-453 cells exclusively in G1 phase^[1]. Palbociclib (500 nM, 7 days) hydrochloride increases expression of homologous genes (H2d1, H2k1, and B2m) in MDA-MB-453 and MDA-MB-361 cells^[2].

Palbociclib (0-1 μ M, 6 days) hydrochloride inhibits growth of several luminal ER-positive as well as HER2-amplified breast cancer cell lines, with IC₅₀ values ranging from 4 nM to 1 μ M^[3].
 Palbociclib (0-1 μ M, 3 days) hydrochloride inhibits the proliferation of human liver cancer cell lines with IC₅₀ values ranging from 0.01 μ M to 3.49 μ M, and induces a reversible cell cycle arrest^[4].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 Cell Proliferation Assay^[3]

Cell Line:	ER-positive as well as HER2-amplified breast cancer cell lines (MDA-MB-175, ZR-75-30, CAMA-1, etc.)
Concentration:	0-1 μ M
Incubation Time:	6 days
Result:	Inhibited growth of luminal ER-positive as well as HER2-amplified breast cancer cell lines.

Cell Cycle Analysis^[1]

Cell Line:	MDA-MB-453 cells
Concentration:	0-1 μ M
Incubation Time:	24 h
Result:	Arrested MDA-MB-453 cells in G1.

In Vivo

Palbociclib (oral administration, 75 or 150 mg/kg, daily for 14 days) hydrochloride produces rapid tumor regressions and delays tumor growth^[1].
 Palbociclib (oral administration, 90 mg/kg, daily for 12 days) hydrochloride reduces Treg numbers and the Treg:CD8 ratio in the spleen and lymph nodes in tumor-free mice, demonstrating the tumor-independent effects^[2].
 Palbociclib (oral administration, 100 mg/kg, daily for 1 week) hydrochloride has potent antitumour effects in genetically engineered mosaic mouse model of liver cancer^[4].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice bearing Colo-205 colon carcinoma xenografts (p16 deleted) ^[1]
Dosage:	75, 150 mg/kg
Administration:	Oral administration; daily for 14 days
Result:	Produced rapid tumor regressions and a corresponding tumor growth delay of ~50 days.

Animal Model:	Tumor-free female FVB mice ^[2]
Dosage:	90 mg/kg
Administration:	Oral administration; daily for 12 days
Result:	Reduced total thymic mass and immature CD4 ⁺ and CD8 ⁺ double-positive thymocytes, and increased the fractions of CD4 ⁺ and CD8 ⁺ single-positive thymocytes.

Animal Model:	Genetically engineered mosaic mouse model of liver cancer (Myc;p53-sgRNA) ^[4]
Dosage:	100 mg/kg

Administration:	Oral administration; daily for 1 week
Result:	Decreased the luminescence signal in liver and delayed tumour growth.

CUSTOMER VALIDATION

- Nature. 2020 Jul;583(7817):620-624.
- Nature. 2017 Aug 24;548(7668):471-475.
- Nature. 2017 Jun 15;546(7658):426-430.
- Cancer Cell. 2017 Apr 10;31(4):576-590.e8.
- Nat Methods. 2022 Mar;19(3):331-340.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.
- [2]. Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475.
- [3]. Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
- [4]. Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA